SCHEMBL285784

SCHEMBL285784

CCCCc1noc(C)c1C=Cc1nc(C)c(C(=O)OCC(N)=O)s1

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 1/20 0.35
ALDH1A1 P00352 5/20 0.33
HSD17B10 Q99714 2/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
KDM4E B2RXH2 6/20 0.32
MAPT P10636 3/20 0.32
NPSR1 Q6W5P4 2/20 0.32
DHODH Q02127 2/20 0.32
CDC7 O00311 1/20 0.32
DBF4 Q9UBU7 1/20 0.32
HPGD P15428 5/20 0.32
RAB9A P51151 2/20 0.31
NPC1 O15118 1/20 0.31
POLB P06746 1/20 0.31
MEN1 O00255 2/20 0.31
KMT2A Q03164 2/20 0.31
LMNA P02545 2/20 0.30
HTT P42858 2/20 0.30
MAPK1 P28482 1/20 0.30
SMN1; SMN2 Q16637 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL285901 0.87 POLB (0.42) TSHRALDH1A1HSD17B10L3MBTL1KDM4E
SCHEMBL285902 0.87 POLB (0.42) TSHRALDH1A1HSD17B10L3MBTL1KDM4E
SCHEMBL285868 0.87 IKBKB (0.35) LMNA
SCHEMBL285869 0.87 IKBKB (0.35) LMNA
SCHEMBL285997 0.85 KMT2A (0.36) TSHRPOLBKMT2A
SCHEMBL2749746 0.83 ALDH1A1 (0.38) TSHRALDH1A1L3MBTL1KDM4EHPGD
SCHEMBL286202 0.83 ALDH1A1 (0.38) TSHRALDH1A1L3MBTL1KDM4EHPGD
SCHEMBL286203 0.83 ALDH1A1 (0.38) TSHRALDH1A1L3MBTL1KDM4EHPGD
SCHEMBL286047 0.82 CDC7 (0.34) ALDH1A1L3MBTL1KDM4ECDC7DBF4
SCHEMBL285632 0.81 ALDH1A1 (0.35) ALDH1A1HSD17B10L3MBTL1KDM4EMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2427459-A1 ISOXAZOLE-THIAZOLE DERIVATIVES AS GABA A RECEPTOR INVERSE AGONISTS FOR USE IN THE TREATMENT OF COGNITIVE DISORDERS F. Hoffmann-La Roche AG (CH) 2012-03-14 EP disclosed